PHVS Stock Recent News

ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at two upcoming congresses: the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA), to be held from March 14-16, 2024, in Milan, Italy, and the 2024 HAE International (HAEi) Regional Conference Americas, to be held from March 15-17, 2024, in Panama City, Panama. Details of the presentations are as follows:

ZUG, Switzerland, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for poster presentation at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting 2024, to be held from February 4-8, 2024, at the Grand Hyatt Kauai Resort & Spa in Koloa, Hawaii.

Pharvaris (PHVS) rises 6% after the FDA lifts the clinical hold on the investigational candidate, deucrictibant, for the prophylactic treatment of HAE attacks.

Data from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%.

Pharvaris (NASDAQ: PHVS ) stock is rising higher on Wednesday after the clinical-stage biopharmaceutical company announced an underwritten offering for its shares. That offering includes 11,125,000 shares of PHVS stock sold to one investor for a price of $24 each.

Shares of Pharvaris N.V. PHVS, +14.98% jumped 40% premarket on Wednesday after the Switzerland-based company said an investigational drug met its primary goal in a clinical trial for treatment and prevention of hereditary angioedema attacks.

ZUG, Switzerland, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of one abstract for oral presentation and two abstracts for poster presentation at the GA²LEN UCARE Conference 2023, to be held from December 7-9, 2023, at the Rebouças Convention Center in São Paulo, Brazil.

ZUG, Switzerland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2023 Annual Scientific Meeting, to be held from November 9-13, 2023, at the Anaheim Convention Center in Anaheim, CA.

ZUG, Switzerland, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of an abstract oral presentation at the Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI) and Allergy and Clinical Immunology Society of Singapore (ACIS) APAAACI 2023 International Conference, to be held from October 23-26, 2023, at the Suntec Singapore International Convention and Exhibition Center in Singapore.

ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the Consortium of Independent Immunology Clinics (CIIC) Fall 2023 Conference, to be held from October 13-14, 2023, at the Gaylord Texan Resort in Dallas, TX.